MannKind Corporation filings document formal disclosures for a Nasdaq-listed biopharmaceutical company focused on inhaled and drug-device therapies. Its 8-K reports furnish operating results and business updates for Afrezza, Furoscix and pipeline programs, while also recording capital-structure events such as convertible-note settlement and material collaboration agreements involving the Technosphere platform.
The filing record also includes acquisition-related disclosures for the completed scPharma transaction, including acquired-business financial statements and pro forma combined financial information. MannKind proxy materials address annual meeting matters, executive compensation and equity-award information, and other governance subjects tied to its common stock.
MannKind Corp CEO Michael Castagna purchased 100,000 shares of common stock in an open-market transaction at a weighted average price of $2.59 per share on March 10, 2026. Following this purchase, he directly owns 2,575,911 shares. An additional 1,500 shares are held indirectly through his spouse.
MannKind Corp director Shannon James Samuel acquired 12,000 shares of common stock at a price of $3.27 per share. The acquisition was made through the company’s Market Price Stock Purchase Plan, which was approved by the Board of Directors on March 1, 2026.
Following this grant or award acquisition, Samuel’s direct holdings increased to 64,635 shares of MannKind common stock. This transaction reflects participation in a board-approved stock purchase plan rather than an open-market trading decision.
MannKind Corp director Anthony C. Hooper acquired 35,000 shares of common stock on March 1, 2026 at a price of $3.27 per share. The shares were purchased through the company’s Market Price Stock Purchase Plan, which was approved by the board on that date. Following this transaction, Hooper directly owns 236,153 MannKind shares.
MannKind Corp's Chief Financial Officer Christopher B. Prentiss acquired additional company stock through a board-approved purchase plan. On March 1, 2026, he obtained 5,000 shares of common stock at $3.27 per share under the Market Price Stock Purchase Plan. Following this transaction, he directly owned 348,854 shares of MannKind common stock.
MannKind Corp Chief Executive Officer Michael Castagna reported multiple share and option acquisitions. On March 1, 2026, he acquired 15,290 shares of common stock at $3.27 per share through the company’s Market Price Stock Purchase Plan, which was approved by the board.
Following this, his direct common stock holdings rose to 2,475,911 shares. On February 26, 2026, performance milestones were reached for stock options originally granted in 2016 and 2017, leading to partial vesting of options covering 50,000, 57,750, and 37,525 shares, increasing his directly held option awards.
MannKind Corp director Steven B. Binder reported the vesting of performance-based stock options. On February 26, 2026, a defined performance milestone was achieved under an option originally granted on August 24, 2017, resulting in a grant-credited acquisition of 45,025 employee stock options at an exercise price of $0.00 per option.
Thomson David reported acquisition or exercise transactions in this Form 4 filing.
MannKind Corp executive David Thomson reported new option vesting tied to performance goals. On February 26, 2026, 20,000 and 37,525 employee stock options (rights to buy shares) became partially vested from grants originally awarded in 2016 and 2017 after defined performance milestones were achieved.
MannKind Corp executive Stuart A. Tross reported acquisitions of both stock and options. He obtained 15,290 shares of common stock at $3.27 per share through MannKind’s Market Price Stock Purchase Plan, bringing his direct holdings to 1,000,297 common shares. He also acquired stock options for 20,000 and 28,143 shares after performance milestones from 2017 option grants were met on February 26, 2026, resulting in partial vesting of those awards.
MannKind Corporation is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases, aiming to offer patient‑centric drug–device therapies for chronic conditions.
The company currently commercializes three cardiometabolic products: Afrezza inhaled insulin for adults with diabetes, Furoscix for edema in heart failure and chronic kidney disease, and the V‑Go wearable insulin delivery device. It also earns royalties and manufacturing revenue from Tyvaso DPI for pulmonary hypertension, marketed by United Therapeutics, and recently expanded this collaboration to include MNKD‑1501.
MannKind’s pipeline includes MNKD‑201, an inhaled nintedanib for idiopathic pulmonary fibrosis now in Phase 1b and global Phase 2 studies, and MNKD‑701, an early bumetanide inhalation program. Key 2026 regulatory milestones include FDA decisions on an Afrezza pediatric sBLA by May 29, 2026 and a Furoscix ReadyFlow Autoinjector sNDA by July 26, 2026.
Manufacturing is centered in Danbury, Connecticut, where Technosphere powders, inhalers and Tyvaso DPI are produced; V‑Go and many Furoscix components are made by contract manufacturers, including in China. A 2025 FDA inspection of the Connecticut facility concluded without Form 483 observations.
The filing highlights extensive risks, including dependence on United Therapeutics’ continued emphasis on Tyvaso DPI—particularly in light of its newly promoted Tresmi soft‑mist treprostinil candidate—manufacturing and supply‑chain concentration, pricing and reimbursement pressures, evolving U.S. healthcare and privacy laws, and the need for additional capital and successful commercialization to support ongoing operations and growth.
MannKind Corporation reported strong top-line growth for the fourth quarter and full year 2025, driven by its cardiometabolic and inhaled therapies portfolio. Q4 2025 revenues were $111.9 million, up 46% from Q4 2024, with full year 2025 revenues of $349.0 million, a 22% increase over 2024.
Growth came from higher royalties on Tyvaso DPI, increased collaborations and services for United Therapeutics, and rising Afrezza sales, plus $23.2 million of Furoscix revenue added after acquiring scPharmaceuticals in October 2025. Despite this, MannKind recorded a Q4 2025 net loss of $15.9 million and full year 2025 net income of $5.9 million, down from $27.6 million in 2024, as R&D and SG&A spending rose sharply to support pipeline development and the Furoscix launch.